#### **ORIGINAL ARTICLE**



# Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen

Aneta Szudy-Szczyrek<sup>1</sup> • Radosław Mlak<sup>2</sup> • Michał Mielnik<sup>1</sup> • Michał Szczyrek<sup>3</sup> • Aleksandra Nowaczyńska<sup>1</sup> • Iwona Homa-Mlak<sup>2</sup> • Szymon Zmorzyński<sup>4</sup> • Kinga Kuśmierczuk<sup>1</sup> • Jacek Sompor<sup>5</sup> • Agata Filip<sup>4</sup> • Teresa Małecka-Massalska<sup>2</sup> • Marek Hus<sup>1</sup>

Received: 10 June 2019 / Accepted: 17 May 2020 / Published online: 26 May 2020 The Author(s) 2020

#### Abstract

Neutrophils to lymphocytes ratio (NLR) and platelets to lymphocytes ratio (PLR) are considered as laboratory markers of inflammation. They can be potentially useful in predicting the course of multiple neoplasms including selected hematological cancers. The aim of the study was to assess the value of NLR and PLR in predicting the effects of therapy and prognosis in multiple myeloma patients treated with thalidomide-based regimen. The study group consisted of 100 patients treated with the first line CTD (cyclophosphamide, thalidomide, and dexamethasone) chemotherapy. The NLR and PLR were calculated before treatment. High NLR was observed in patients with higher stage of the disease, with poor performance status, hypercalcemia, and high CRP. High PLR was associated with low BMI and high CRP. In patients with high NLR, significantly shorter PFS was observed (17 vs. 26 months, p = 0.0405). In addition, high values of NLR and PLR were associated with significantly shorter OS (38 vs. 79 months, p = 0.0010; 40 vs. 78 months, p = 0.0058). Summarizing, NLR and PLR have a significant independent prognostic value for multiple myeloma patients. Furthermore, the NLR can be a predictive marker for the outcome of thalidomide-based chemotherapy.

Keywords NLR · PLR · Prognostic factors · Multiple myeloma · Thalidomide

Aneta Szudy-Szczyrek anetaszudy@gmail.com

<sup>1</sup> Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland

- <sup>2</sup> Chair and Department of Human Physiology, Medical University of Lublin, 20-080 Lublin, Poland
- <sup>3</sup> Chair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland
- <sup>4</sup> Department of Cancer Genetics with Cytogenetics Laboratory, Medical University of Lublin, 20-080 Lublin, Poland
- <sup>5</sup> Department of Traumatology and Emergency Medicine, Medical University of Lublin, 20-081 Lublin, Poland

# Introduction

Multiple myeloma (MM) is the second most common hematological neoplasm, characterized by the accumulation of malignant plasma cells in the bone marrow leading to anemia, bone pain, renal impairment, hypercalcemia, and infections.

It accounts for about 1% of all malignancies and about 10% of hematologic malignancies. It most often occurs in people in the 7th and 8th decade of life, significantly more often in men [1]. The advances made in the treatment of multiple myeloma in the last few decades, starting from the use of autologous hematopoietic stem cell transplantation, followed by the introduction of innovative therapies based on immunomodulatory drugs and proteasome inhibitors, radically improved the prognosis in this group of patients. According to current statistics, the percentage of 5-year survival is currently 48.5% and the median overall survival (OS) exceeded 6 years.

Unfortunately, MM is still considered to be an incurable disease [2].

Traditional, classic prognostic factors for multiple myeloma patients include the stage of the disease, performance status, age, and comorbidities. There is a high interest in a number of factors, both genetic, biochemical and hematological, and their potential use as prognostic markers [3, 4]. Markers of inflammation are particularly interesting. It is believed that they can indirectly reflect the status of the bone marrow microenvironment, which affects the processes of regulation and promotion of growth, survival, migration, and even drug resistance of myeloma cells [5].

The aim of the study was to assess the prognostic and predictive value of NLR and PLR ratios calculated on the basis of the absolute number of neutrophils, lymphocytes, and platelets in patients with multiple myeloma treated with thalidomide-based induction chemotherapy.

## Materials and methods

The study group consisted of 100 multiple myeloma (MM) patients aged 53-69 years (median 64). All patients received triplet CTD induction therapy in 28-day cycles, in the following doses: thalidomide 100 mg/day p.o., cyclophosphamide 300-500 mg/week p.o., and dexamethasone 10-20 mg/day p.o. on days 1-4 and 8-11. The median of cycles of chemotherapy was 6. The median follow-up was 41.5 months. Demographic and clinical data including sex, age, stage, and type of disease were collected. An analysis of classic cytogenetic and biochemical prognostic factors (deletion of 17p, t(4;14) translocation, t(14;16) translocation,  $\beta 2$  microglobulin, LDH, CRP), NLR, and PLR (calculated as ratios of absolute neutrophil count to lymphocyte and platelet counts before treatment) was performed. In publications on the importance of NLR and PLR in assessing the prognosis of solid tumors, authors provide various cut-off points for NLR and PLR. To find the optimal values, we analyzed the ROC curves, which allowed to set the cut-off points: 2.86 for NLR and 157.66 for PLR. Data regarding treatment, such as the number of chemotherapy cycles, type of response, progression-free survival (PFS), and overall survival (OS), were also documented.

Statistical analysis of the obtained data was carried out using MedCalc 15.8 (MedCalc Software, Belgium) and Statistica 10 (Statsoft, USA) computer software. The comparison of the values of selected laboratory markers, demographic, and clinical factors was carried out using the non-parametric U Mann-Whitney test. The correlation between selected demographic, clinical and laboratory factors, as well as NLR and PLR was carried out using Spearman's rank correlation. The analysis of ROC curves was used to determine the cut-off points for NLR and PLR. The Kaplan-Meier estimation method and Cox logistic regression were used to assess the probability of survival and the occurrence of progression depending on the distribution of the studied factors. In all used tests, results with p values < 0.05 were considered statistically significant.

#### Results

# Influence of demographic and clinical factors on studied laboratory parameters

The distribution of the values of the examined laboratory parameters (NLR, PLR) was not significantly correlated with factors such as sex, age, type of the disease (secretory or non-secretory MM), type of monoclonal protein, class of light chains, percentage of plasma cells in bone morrow, and specific cytogenetic abnormalities: (del(17p), t(4:14), and t(4:16)) (Fig. 1). Among the studied factors, only disease stage according to Durie-Salomon scale was significantly related to the NLR index. Statistically significantly higher NLR values were observed in patients at a higher Durie-Salomon stage (III vs. I or II: 2.06 vs. 1.43, p = 0.0404; Fig. 2). Detailed information on the comparison of the values of selected laboratory indicators depending on demographic and clinical factors are included in the Table 1.

However, we noted a statistically significant weak positive correlation between the performance status and NLR (rho = 0.197, p = 0.0492; Fig. 1a). In addition, this indicator correlated positively with serum calcium concentration and CRP (weak, rho = 0.223, p = 0.0258, moderate, rho = 0.449, p < 0.0001; respectively; Fig. 1b, c). Furthermore, PLR also correlated positively with CRP (weak, rho = 0.225, p = 0.0311; Fig. 1d). This indicator showed a negative correlation with BMI (rho = -0.300, p = 0.0429; Fig. 1e). There was also a moderate, positive correlation between NLR and PLR (rho = 0.453, p = 0.0091; Fig. 1f). Spearman's correlations are shown in the Table 2.

#### Response

There were no statistically significant differences between studied laboratory indicators: NLR and PLR and the type of clinical response obtained during thalidomide-based chemotherapy (CTH) cycles (Tables 1 and 2). However, ROC curve analysis (Table 3) showed that NLR might be useful in



**Fig. 1** a Spearman's correlation between performance status and NLR. **b** Spearman's correlation between CRP serum concentration and NLR. **c** Spearman's correlation between calcium serum concentration and NLR.

**d** Spearman's correlation between CRP and PLR. **e** Spearman's correlation between BMI and PLR. **f** Spearman's correlation between PLR and NLR

predicting response after the 6th cycle of CTH (48.6% sensitivity and 100% specificity; AUC = 0.76, 95% CI 0.65–0.85; p = 0.0303; Fig. 3a). On the other hand,

PLR showed 94.4% sensitivity and 50% specificity in detection of response after 8th cycle of CTH (AUC = 0.77, 95% CI 0.56–0.90; p = 0.0011; Fig. 3b).

18 20

600

16

500

n

500

600





# Survival analysis

Median number of treatment cycles was 6 (range 1–12). Median PFS was 24 months and OS 69 months. Half of the patients (50%) were subjected to autologous hematopoietic stem cell transplantation (auto-HSCT). Median time to auto-HSCT was 12 months (range 1–36 months). Auto-HSCT was associated with significant extension of PFS (28 vs. 17 months; HR = 0.55, 95% CI 0.35–0.87, p = 0.0041) and OS (54 vs. 40 months; HR = 0.40, 95% CI 0.23–0.70, p = 0.0003).

A significant longer median PFS was observed in patients with Durie-Salomon stage I or II (26 vs. 8 months; HR = 0.52, 95% CI 0.25–1.12, p = 0.0258). Similarly, longer PFS was noted in patients with normal renal function (A) (26 vs. 10 months; HR = 0.49, 95% CI 0.23–1.07, p =0.0146) and normal ALB serum concentration (28 vs. 10 months; HR = 0.54, 95% CI 0.34–0.88, p = 0.0048). We also observed that patient with pre-treatment eGFR of more than 60 had about twice longer PFS compared to others patients (G3a/G3b/G4/G5D) (78 vs. 38 months, respectively; HR = 0.50, 95% CI 0.26–0.97; p = 0.0121) (Fig. 4a). On the other hand, shorter median PFS was observed in carriers of translocation (t4;14) (4 vs. 24 months; HR = 3.91, 95% CI 0.96–15.86, p = 0.0002) and interestingly in patients with higher NLR.

There was a significant difference in OS among patients with different staging. Patients in ISS stage I or II had significantly longer median OS compared to subjects with stage III (78 vs. 38 months; HR = 0.55, 95% CI 0.30–0.98; p = 0.0241). Among patients with normal renal function ("A" according to the Durie-Salmon scale), significant extension of OS was observed (78 vs. 33 months; HR = 0.42, 95% CI

0.16-1.14; p = 0.0126). Weight loss before treatment (defined as loss of at least 5% of body weight) was a significant factor associated with OS shortening (38 vs. 82 months; HR = 3.11, 95% CI 1.75–5.51; p < 0.0001). Male sex was associated with significantly higher risk of OS shortening (50 vs. 81 months; HR = 2.03, 95% CI 1.18–3.50; p = 0.0190). Among the analyzed cytogenetic abnormalities, the presence of translocation t(4;14) was associated with significant OS shortening (33 vs. 56 months; HR = 2.60, 95% CI 0.74–9.22; p = 0.0288). Significant OS extension was observed in patients with normal ALB level (78 vs. 38 months; HR = 0.57, 95% CI 0.32-1.01; p = 0.0381) as well as normal creatinine level (78 vs. 38 months; HR = 0.50, 95% CI 0.26–0.96; p = 0.0119). Interestingly, both high NLR and PLR were significantly associated with higher risk of OS shortening (38 vs. 79 months; HR = 2.45, 95% CI 1.22–4.49; *p* = 0.0010; Fig. 4b); 40 vs. 78 months; HR = 2.15, 95%CI 1.07–4.33; *p* = 0.0058; Fig. 4c; respectively). Results of univariate PFS and OS analysis were presented in Table 2.

Multivariate analysis using Cox's regression model (Table 3) revealed factors which were independently associated with significantly higher risk of OS shortening: male sex (p = 0.0012; HR = 12.88, 95% CI 2.75–60.34), the presence of translocation (t4;14: p = 0.0218; HR = 3.84, 95% CI 1.22–12.07), weight loss before treatment (p = 0.0001; HR = 11.39, 95% CI 3.50–37.08), low ALB level (p = 0.0235; HR = 3.28, 95% CI 1.18–9.11), high NLR (p = 0.0133; HR = 5.00, 95% CI 1.41–17.75), and PLR (p = 0.0496; HR = 2.56, 95% CI 1.01–6.51). Factors which were independently associated with significantly higher risk of PFS shortening included presence of translocation t4;14 (p < 0.0001; HR = 15.18, 95% CI 4.98–46.26), low ALB level (p = 0.0021; HR = 3.47, 95% CI 1.58–7.64), higher serum concentration of creatinine (p =

#### Table 1 Comparison of the values of selected laboratory indicators depending on demographic and clinical factors

Sex         1.79         0.3903         122.74         0.6200           Men         1.20         0.3903         111.63         0.6200           Age	Variable	NLR Me	р	PLR Me	р
Men1.790.390312.740.6300Ape2.03111.63Ape1.920.6987115.451.920.6987115.45Diagnois1.970.6696119.400.4116Secretary (1)1.970.6696119.400.4116Light chin disease (2)1.970.6696119.400.4116Non-secretary ryhasmabasite (3)1.076.8391Non-secretary ryhasmabasite (3)1.920.7449117.440.8466plasmacyroma1.920.7449117.440.8466plasmacyroma1.920.7449117.440.8466plasmacyroma1.920.7449117.440.8466plasmacyroma1.920.7469118.460.5581Light chin diseae1.730.0587126.020.5812Light chin rye1.7311.640.55810.5581Light chin rye1.510.222118.460.5581Light chin rye1.510.2522118.460.5581Light chin rye1.510.3567126.070.5727II1.510.3567122.770.3785111.49Uif chin rye1.510.3567122.770.3785III1.510.3567122.770.3785111.49III1.510.3567122.770.3785114.66III1.71107.66172.40172.40172.40III1.380.4044105.69 </td <td>Sex</td> <td></td> <td></td> <td></td> <td></td>	Sex				
Women203111.3Age	Men	1.79	0.3903	122.74	0.6200
Age         view	Women	2.03		111.63	
< 601.920.6987119.200.5320> 601.93115.45DagnosisSecretory (1)1.970.6696119.40Light chain disease (2)1.86109.28Non-secretory bismablastic (3)1.076.8.39Non-secretory bismablastic (3)1.076.8.39Non-secretory bismablastic (3)1.920.74491.7.44Non-secretory bismablastic (3)1.920.74491.7.44Non-secretory bismablastic (3)1.961.7.301.86Jessmay toma1.961.7.301.16.43.892IgG1.7.30.05871.6.020.3892IgG1.7.30.05871.16.40.3892IgG1.7.31.16.40.38921.8.66Darie Salmon stage1.8.61.8.66I II1.510.22821.2.7.710.9456I II1.430.404410.65.90.5277III1.430.404410.65.90.5277III1.430.404410.65.90.5277III1.510.356712.7.710.7385II, III1.970.76118.26118.26II, III1.430.404410.65.90.5277II, III1.510.356712.7.710.7385II, III1.430.404410.65.90.5277II, III1.430.404410.65.90.5287II, III1.430.404410.65.90.5287 <td>Age</td> <td></td> <td></td> <td></td> <td></td>	Age				
> 00 193 193 1545 Toggnosis Secretory (1) 197 0.6696 1940 0.4116 Light chain disease (2) 188 190.28 Non-secretory/plasmablastic (3) 107 68.39 Non-secretory plasmaptoma (4) 2.0 1973 1874 0.8466 plasmacytoma (5) 192 0.7449 17.74 0.8466 plasmacytoma (5) 192 0.7449 17.74 0.8466 plasmacytoma (5) 192 0.7449 117.44 0.8466 plasmacytoma (5) 192 0.7449 111.64 0.8581 Light chain type Kappa 1.75 0.0587 126.72 0.9467 192.00 Light chain type Light c	< 60	1.92	0.6987	119.20	0.5320
DagnosisLight chain disease (2)1.870.696119.400.4116Light chain disease (2)1.86109.280.93.5Non-secretory/plasmadytom (4)2.20190.35100.28Secretory, Light chain disease1.920.7449117.440.8466plasmacytom (a)1.96137.300.8466plasmacytom (a)2.730.058712.6020.3892Monoclonal protein class1.730.058712.6020.3892Light chain type1.730.4662109.200.5581Lambda2.20118.46118.46118.46Light chain type1.510.2282122.770.9456Lambda2.04118.66118.66118.66Light chain type1.430.40440.65.990.5727Light Chain type1.510.2367122.770.7385Light Chain1.510.3587122.770.7385Light Chain1.610.3567122.770.7385Light Chain1.610.762122.770.7385Light Chain1.71107.66123.900.23962.31.711.74107.76124.902.31.8011.8911.89124.902.31.8011.89124.900.8522.31.8011.89124.900.8522.31.8011.89124.900.8522.31.80138.90124.900.852 <trr>2.31.8</trr>	> 60	1.93		115.45	
Secretory (1)         1.97         0.6696         119.40         0.4116           Ligh chain disease (2)         1.86         190.35         190.35           Non-secretory/plasmablastic (3)         107         68.39         190.35           Secretory. Iphamablastic (3)         197         7.449         137.40         0.8466           plasmacytoma         196         7.749         117.44         0.8466           plasmacytoma         197         0.0587         126.02         0.3892           IgG         1.73         0.166         0.581         0.373           Ligdt chain type         1.75         0.4602         0.18.40         0.5581           Lambda         2.20         118.46         0.5581         0.5581           Limbda         2.20         118.46         0.456         0.5727           IL         1.31         0.2282         12.77         0.5385           IL         1.43         0.0404         106.59         0.5727           IL         1.43         0.0404         106.59         0.5727           IL         1.43         0.0404         106.59         0.5727           IL         1.44         126.0         0.4770         11	Diagnosis				
Non-secretory/plasmabiant: (3)10768.39Non-secretory/plasmabiant: (3)2.20190.35Secretory. Light chain disease1.2017.4017.40Mon-secretory: plasmabiant: 1.961.7317.400.8466Jasmacytoma1.9617.3011.06Monoclonal protein class1.7311.060.3892Ligd Chain type2.730.058712.6020.3892Ligd Chain type2.20118.460.55811.160.228212.770.9456Limbda2.01118.061.4080.44400.65.990.578711.160.44620.7370.7385III1.510.228212.770.945611.4080.44400.65.990.572711.8.0611.8.261.710.738511.620.572711.8260.572711.8261.710.738511.8261.710.738511.740.738511.741.710.738511.741.710.73651.711.710.73651.711.711.710.7361.711.710.7361.711.710.7361.711.710.7361.721.720.33823.3571.14.060.3922.3263.3571.18.961.321.321.321.321.321.321.321.321.321.321.321.331.341.340.90752.040.3523.3571.14.060.3523.3571.18.961.321.321.321.321.32<	Secretory (1) Light chain disease (2)	1.97 1.86	0.6696	119.40 109.28	0.4116
Non-secretory/plasmacytoma (4)         2.20         190.35           Secretory. Light chain disease         1.92         0.7449         17.74         0.8466           plasmacytoma         1.96         137.30         100         0.8466           plasmacytoma         1.96         137.30         100         0.8466           plasmacytoma         1.96         137.30         100         0.8892           IgG         1.73         0.0587         126.02         0.892         126.02         0.892           IgG         1.73         0.4602         109.20         0.5581         0.5581           Lambda         2.20         109.20         0.5581         0.158         0.2282         12.77         0.9456           Iambda         2.04         14.08         0.140.00         0.57         0.97         0.77         0.7385           III         1.97         0.3567         12.2.77         0.7385         0.376         11.80         0.4700           IS stage         1.97         0.3567         12.77         0.7385         0.3004         140.60         0.975           IS stage         1.97         1.97         10.99         0.3852         0.290         0.3162         0.2	Non-secretory/plasmablastic (3)	1.07		68.39	
Secretory. Light chain disease         1.92         0.7449         17.44         0.8466           Non-secretory. plasmabilistic         1.92         0.749         17.30         0.886           IgG         1.73         0.0587         126.02         0.3892           IgG         1.73         0.0587         126.02         0.3892           Light chain type         1.73         0.4602         109.20         0.5581           Light chain type         2.20         118.46         0.5581           Light chain type         2.20         118.46         0.4602         0.920         0.5581           Light chain type         2.20         118.46         0.4602         0.5581         0.4602         0.5581           Light chain type         2.20         118.46         0.4602         0.5581         0.4662         0.5581           Light chain type         1.51         0.2282         122.77         0.4566         0.5727         118.66         118.26         117.41         158         158.26         117.41         158.26         127.41         158         158.26         127.71         173.24         158.26         127.71         173.24         159         129.277         10.716         159         129.277 <td>Non-secretory/plasmacytoma (4)</td> <td>2.20</td> <td></td> <td>190.35</td> <td></td>	Non-secretory/plasmacytoma (4)	2.20		190.35	
Non-serieory: plasmabilistic         192         0.7449         17.44         0.8466           plasmatytoma         137.30         137.30         137.30         137.30           Monoclonal protein class         17.3         0.0587         126.02         0.8992           IgG         1.73         0.0587         126.02         0.8992           IgG         1.76         0.4602         109.20         0.5581           Lambda         2.20         114.68         0.5581           Durie-Salmon stage         1.3         0.2582         12.77         0.9456           II         1.51         0.2822         12.77         0.9456           III         1.43         0.0404         106.59         0.572           III         1.43         0.3567         122.77         0.7385           II, III         1.43         0.3567         122.77         0.7385           IS stage         171         10.76         174         0.746           Stage         120.4         0.782         120.90         0.376           12         2.04         0.786         126.90         0.302           13         1.80         111.89         111.89         111.89	Secretory. Light chain disease				
Monoclonal protein class         J2,73         0.0587         12.6.02         0.882           IgG         1.73         0.0587         12.6.02         0.882           Ligdt chain type         1.76         0.4602         109.20         0.5581           Light chain type         1.76         0.4602         109.20         0.5581           Light chain type         1.76         0.4602         109.20         0.5581           Durie-Salmon stage         1         1.81         0.2282         122.77         0.9456           II         1.38         0.4044         106.59         0.5727           III         2.04         118.26         0.7277         0.7385           III         2.04         0.3567         122.77         0.7385           II, III         1.97         17.74         0.76         0.777           III         2.04         0.7824         126.90         0.470           2         1.71         107.76         0.778         0.778           3         1.80         111.89         0.2396         0.2396           2.1         2.04         0.782         10.909         0.2396           2.3         1.78         10.909	Non-secretory: plasmablastic plasmacytoma	1.92 1.96	0.7449	117.44 137.30	0.8466
IgA         2.73         0.0587         126.02         0.3892           IgG         1.73         111.64         111.64         0.3892           Light chain type         2.20         109.20         0.5581           Lambda         2.20         118.46         0.5581           Durie-Salmon stage         1         1.51         0.2282         122.77         0.9456           II         1.51         0.2282         122.77         0.9456           II         1.51         0.2282         122.77         0.9456           II         1.51         0.2282         122.77         0.9456           III         1.26         0.5267         118.26         0.5727           III         2.06         118.26         0.5727         0.7385           III         1.51         0.5367         122.69         0.5727           III         1.61         0.3657         122.69         0.5727           III         1.57         0.5567         122.69         0.5727           IS stage         1         1.71         107.76         0.566           1.5         2.04         0.7526         126.90         0.2362           1.2	Monoclonal protein class				
jeg G         1.73         111.64           Light chain type	IgA	2.73	0.0587	126.02	0.3892
Light chain type       1.76       0.4602       109.20       0.5581         Lambda       1.76       0.4602       118.46       0.5581         Durie-Salmon stage       1       1.51       0.2282       12.77       0.9456         II       1.38       0.404       106.59       0.5727         III       0.40       106.59       0.5727         III       1.43       0.404       106.59       0.5727         III       1.51       0.3567       122.77       0.7385         I, III       1.97       0.3567       122.77       0.7385         I, III       1.97       0.762       107.40       0.7824         Stage       1.71       107.76       0.4770         1.51       0.51       0.566       126.90       0.2396         2.3       1.78       109.82       0.209       0.3523         1.2       2.04       0.566       109.82       0.209         2.3       1.78       109.82       118.99       0.304       114.06       0.9075         1.2       2.04       0.566       120.61       0.79       120.61       120.61       120.61       120.61       120.61       120.61 <t< td=""><td>IgG</td><td>1.73</td><td></td><td>111.64</td><td></td></t<>	IgG	1.73		111.64	
Kappa Lambda         1.76         0.4602         109.20         0.5581           Lambda         2.00         118.46         0.5581           Durie-Salmon stage         1         1.51         0.2282         122.77         0.9456           II         1.38         114.08         114.08         0.9456           III         1.38         0.4044         106.59         0.5727           III         2.06         182.6         0.7385           I, III         0.3567         122.77         0.7385           I, III         1.51         0.3567         122.77         0.7385           I, III         0.3767         122.77         0.7385         0.7727           IS stage         1         1.0         0.3567         122.77         0.7385           I, III         1.97         0.3567         122.77         0.7385           I, III         1.71         107.76         122.77         0.776           IS stage         1.80         111.89         111.89         123.23         111.89         123.23         111.89         123.23         120.61         123.23         120.61         123.24         123.61         123.14         123.14         123.14	Light chain type				
Lambda         2.20         118.46           Durie-Salmon stage         1         1         1           I         1.51         0.2282         12.77         0.9456           II         1.38         114.08         0.9456           III         2.04         18.06         0.59         0.5727           I, II         1.43         0.0404         106.59         0.5727           II         1.61         0.3567         122.77         0.7385           I, III         1.51         0.3567         122.77         0.7385           II, III         1.51         0.3567         122.77         0.7385           II, III         1.57         0.3567         122.77         0.7385           II, III         1.71         0.76         0.4770           2         0.4         0.7824         126.90         0.2396           2.3         1.80         111.89         0.2396         0.2396           2.3         1.80         111.89         0.2396         0.3092         120.49         0.3852           12.2         0.00         0.775         120.49         0.3852         120.61         7           12.8         0.3004	Kappa	1.76	0.4602	109.20	0.5581
Durie-Salmon stage       1.51       0.282       12.77       0.9456         II       1.38       114.08       114.08         III       2.04       118.06       118.26       0.5727         III       2.06       118.26       0.5727         III       1.61       0.3567       12.277       0.7385         I, III       1.51       0.3567       12.277       0.7385         I, III       1.97       117.44       107.76       117.44         ISS stage       1       107.76       117.44       109.776         3       1.71       107.76       118.90       0.2396       0.2396         2,3       1.78       109.82       0.2396       0.2396       0.2396         2,3       1.80       111.89       0.2049       0.3523       0.2049       0.3523         1.2       2.04       0.5566       126.90       0.2396       0.3075       114.90       0.975         1.2       1.80       111.89       111.89       0.9975       120.49       0.8528         3       1.80       1.20.49       0.3527       114.06       0.8528         Present       1.98       0.5287       114.06 <t< td=""><td>Lambda</td><td>2.20</td><td></td><td>118.46</td><td></td></t<>	Lambda	2.20		118.46	
I       1.51       0.282       12.77       0.9456         II       1.38       114.08       114.08         III       2.04       118.06       118.06         I, II       1.43       0.0404       106.59       0.5727         III       1.51       0.3567       122.77       0.7385         I, III       1.97       117.44       155       118.26       0.4770         ISS stage       1       1.97       107.76       0.4770         2       0.4       0.7824       126.90       0.4770         2.04       0.7566       126.90       0.2396         2.3       1.78       109.82       0.2396         2.3       1.80       111.89       0.3852         3       1.80       111.89       0.3852         3       1.80       111.89       0.3852         3       1.80       114.96       0.975         1.18       1.38       114.96       0.8582         9       1.80       114.96       0.8582         9       1.98       0.5287       114.06       0.8582         Present       1.98       0.5287       140.06       8.828      P	Durie-Salmon stage				
II     1.38     114.08       III     2.04     118.06       I, II     1.43     0.0404     106.59     0.5727       III     2.06     118.26     0.5727       II     1.51     0.3567     122.77     0.7385       I, III     1.51     0.3567     122.77     0.7385       I, III     1.51     0.3567     122.77     0.7385       I, III     1.51     0.3567     126.90     0.4770       2     0.4     0.7824     126.90     0.4770       2     1.71     107.76     0.7385       3     1.80     .019.82     0.6903       1     2.04     0.5566     126.90     0.2396       2.3     1.78     .0608.2     0.8382       1.2     2.00     0.9775     120.49     0.3852       3     1.80     .019.8     0.3004     114.06     0.9075       3     1.82     120.61     .118.9     118.9       Deletion 17p     1.32     120.61     .20.49     .8282       Present     1.38     .5287     114.06     0.8828       Present     1.88     .5287     120.61     .5287       Tanslocation t(4;16)     .125.14     .521	Ι	1.51	0.2282	122.77	0.9456
III     2.04     18.06       I, II     1.43     0.0404     106.59     0.5727       III     2.06     118.26     1       I     1.51     0.3567     122.77     0.7385       II, III     1.97     17.44     107.76     1       ISS stage     1     107.76     1     1       1     2.04     0.7824     126.90     0.4770       2     1.71     107.76     1     1       1     2.04     0.5566     126.90     0.2396       2.3     1.78     109.82     1     109.82       1.2     2.00     0.9775     120.49     0.3852       3     1.80     111.89     1     1       1.2     2.00     0.9775     120.49     0.3852       3     1.80     111.89     1     1       1.2     2.00     0.9775     120.49     0.3852       3     1.83     114.06     0.8075       Present     1.32     120.61     1       Translocation t(4;14)     125.14     125.14     1       Translocation t(4;16)     1.83     -     120.61     -       Read function     1.83     -     120.61     - <t< td=""><td>II</td><td>1.38</td><td></td><td>114.08</td><td></td></t<>	II	1.38		114.08	
I,II       1.43       0.0404       106.59       0.5727         III       2.06       118.26       118.26         I,III       1.51       0.3567       122.77       0.7385         I,III       1.97       117.44       0.7824       126.90       0.4770         ISS stage       1       107.76       107.76       0.7385         1       2.04       0.7824       126.90       0.4770         2       1.71       107.76       107.76       0.2396         3       1.80       111.89       0.975       120.49       0.3852         1,2       2.00       0.9775       120.49       0.3852         3       1.80       111.89       0.3004       114.06       0.9075         1,2       2.00       0.9775       120.49       0.3852         3       1.80       111.89       111.89       125.14       0.3061       0.3061       0.3061       0.9075         Present       1.38       0.5287       114.06       0.8828       0.5287       125.14       0.8828         Present       1.38       -       57.03       -       2.04       0.521       -         Absent       0.45 <td>III</td> <td>2.04</td> <td></td> <td>118.06</td> <td></td>	III	2.04		118.06	
III       2.06       118.26         I       1.51       0.3567       122.77       0.7385         II, III       1.97       117.44       117.44         ISS stage       1       107.76       0.4770         2       2.04       0.7824       126.90       0.4770         2       1.71       107.76       0.5566       126.90       0.2396         3       1.80       111.89       0.982       0.982         1.2       2.00       0.9775       120.49       0.3852         3       1.80       111.89       0.982       0.975         1.2       2.00       0.9775       120.49       0.3852         3       1.80       111.89       0.9075         7       1.80       111.89       0.9075         9       0.3004       114.06       0.9075         9       1.98       0.3004       14.06       0.8828         9       1.98       0.3004       14.06       0.8828         9       1.83       125.14       17.96       18.96         17       1.85       120.61       -       17.96         18       1.92       0.3062       14.94 </td <td>I, II</td> <td>1.43</td> <td>0.0404</td> <td>106.59</td> <td>0.5727</td>	I, II	1.43	0.0404	106.59	0.5727
1       1.51       0.3567       122.77       0.7385         II, III       1.97       117.44       135         ISS stage       1       17.4       107.76         2       1.71       107.76       0.4770         2       1.71       107.76       0.2396         3       1.80       111.89       0.982         1       2.04       0.5566       126.90       0.2396         2,3       1.78       109.82       0.3052       0.3052       0.3052         1.2       2.00       0.9775       120.49       0.3852         3       1.80       111.89       0.3004       140.60       0.9075         7       1.98       0.3004       140.60       0.9075         7       1.98       0.3004       140.60       0.9075         7       1.38       120.61       120.61       120.61         7       1.38       125.14       120.61       120.61         7       1.38       120.61       1.5       120.61       120.61         7       1.83       -       120.61       1.5       120.61       1.5         1       1.35       -       120.61	111	2.06		118.26	
IA III       1.71       117.44         ISS stage       2.04       0.7824       126.90       0.4770         2       1.71       107.76       107.76         3       1.80       111.89       111.89         1       2.04       0.5566       126.90       0.2396         2, 3       1.78       109.82       0.2396         1,2       2.00       0.9775       120.49       0.3852         3       1.80       111.89       111.89         Deletion 17p       132       120.61       111.89         Absent       1.98       0.3004       114.06       0.9075         Fresent       1.32       120.61       111.89       111.89         Absent       1.98       0.5287       114.06       0.8828         Present       1.32       125.14       125.14       125.14         Translocation t(4;16)       1.38       -       57.03       -         Absent       1.98       0.5287       114.06       0.8828         Present       0.75       57.03       -       -         Present       1.32       105.21       -       -         Absent       1.92 <t< td=""><td></td><td>1.51</td><td>0.3567</td><td>122.77</td><td>0.7385</td></t<>		1.51	0.3567	122.77	0.7385
1       2.04       0.7824       126.90       0.4770         2       1.71       107.76       0         3       1.80       111.89       0         1       2.04       0.5566       126.90       0.2396         2,3       1.78       109.82       0         1,2       2.00       0.9775       120.49       0.3852         3       111.89       111.89       0       0.875         Deletion 17p       107.76       111.89       0       0.9775       120.49       0.3852         Absent       1.98       0.3004       114.06       0.9075       0.976       0.9775       120.61       0.975         Translocation t(4;14)       132       120.61       10       10       0.8828       125.14       0.8828       125.14	II, III ISS stage	1.97		11/.44	
1       2.04       0.7824       120.90       0.47/0         2       1.71       107.76         3       1.80       111.89         1       2.04       0.5566       126.90       0.2396         2,3       1.78       109.82       0.3852         3       1.80       111.89       0.304       114.06       0.9075         3       1.80       111.89       0.3004       114.06       0.9075         Present       1.98       0.3004       114.06       0.9075         Present       1.32       120.61       120.61       120.61         Translocation t(4;14)       1.38       125.14       8828         Present       1.38       125.14       8828         Present       1.38       120.61       -         Translocation t(4;16)       1.83       -       120.61       -         Absent       1.92       0.3062       119.40       0.4326         Present       1.92       0.3062       119.40       0.4326         B       2.07       105.22       105.22       105.22         Stage of chronic kidney disease       1.97       0.6186       113.63       0.5978      <	155 stage	2.04	0.7924	126.00	0.4770
1       10       1000         3       1.80       111.89         1       2.04       0.5566       126.90       0.2396         2.3       1.78       109.82       03852         1.2       2.00       0.9775       120.49       0.3852         3       1.80       111.89       0.3004       14.06       0.9075         Present       1.98       0.3004       14.06       0.9075         Present       1.98       0.3004       14.06       0.9075         Translocation t(4;14)       1.32       105.14       0.9075         Absent       1.98       0.5287       114.06       0.8828         Present       1.38       125.14       0.8828         Present       1.38       -       120.61         Translocation t(4;16)       1.83       -       120.61         Absent       1.83       -       120.61       -         Present       0.75       57.03       -       120.61         Present       0.75       0.3062       119.40       0.4326         B       2.07       105.22       0.4326         B       2.07       105.22       0.5978	2	2.04	0.7824	126.90	0.4770
1       2.04       0.5566       126.90       0.2396         1.2       2.00       0.9775       120.49       0.3852         3       1.80       111.89       0.3852         3       1.80       111.89       0.3852         Deletion 17p       1.80       111.89       0.3852         Absent       1.98       0.3004       114.06       0.9075         Present       1.32       120.61       0.3014       0.9015         Translocation t(4;14)       1.32       120.61       0.8828         Present       1.38       0.5287       114.06       0.8828         Present       1.38       125.14       0.8828       0.8828         Present       1.38       -       120.61       -         Absent       1.83       -       120.61       -         Present       0.75       57.03       -       -         Absent       1.83       -       120.61       -         Present       0.75       57.03       -       -         Absent       1.92       0.3062       119.40       0.4326         B       2.07       105.22       105.22       105.22	3	1.80		111.89	
1.78     109.82       1,2     2.00     0.9775     120.49     0.3852       3     1.80     111.89     0.3052     0.3052       3     1.80     111.89     0.3052     0.3052       Deletion 17p     1.80     111.89     0.3052     0.3052       Absent     1.98     0.3004     114.06     0.9075       Present     1.32     120.61     0.8828       Present     1.38     0.5287     114.06     0.8828       Present     1.38     0.5287     114.06     0.8828       Present     1.38     125.14     0.8828       Present     1.38     125.14     0.8828       Present     1.83     -     120.61       Absent     1.83     -     57.03       Present     0.3062     119.40     0.4326       Absent     1.92     0.3062     119.40     0.4326       B     2.07     105.22     0.522     0.522       Stage of chronic kidney disease     1.97     0.6186     113.63     0.5978       G1     1.54     137.58     137.58     137.58	1	2.04	0 5566	126.90	0 2396
1.2 32.00 1.800.9775120.49 111.890.3852Deletion 17pAbsent Present1.98 1.320.3004114.06 120.610.9075Translocation t(4;14)Absent Present1.98 1.380.5287 125.14114.06 0.88280.8828Present Present1.98 1.380.5287114.06 125.140.8828Present Present1.98 1.380.5287 125.14114.06 125.140.8828Present Present1.98 0.750.5287 7.03114.06 125.140.8828Present Present1.98 0.750.5287114.06 125.140.8828Present Present1.98 0.750.5287114.06 125.140.8828Present Present1.83 0.75Stage of chronic kidney disease G11.97 1.540.6186 113.63113.63 0.59780.5978 137.58G21.76120.34120.34120.34	2, 3	1.78	0.5500	109.82	0.2390
3       1.80       111.89         Deletion 17p       1.98       0.3004       114.06       0.9075         Absent       1.98       0.3004       114.06       0.9075         Present       1.32       120.61       120.61         Translocation t(4;14)       1.98       0.5287       114.06       0.8828         Present       1.38       125.14       0.8828         Translocation t(4;16)       1.83       -       120.61       -         Absent       1.83       -       120.61       -         Absent       0.75       57.03       -       -         Present       0.75       57.03       -       -         Renal function       1.92       0.3062       119.40       0.4326         B       2.07       105.22       -       -         Stage of chronic kidney disease       1.97       0.6186       113.63       0.5978         G1       1.54       137.58       -       -       -         G2       1.76       120.34       -       -	1.2	2.00	0.9775	120.49	0.3852
Deletion 17p         Absent       1.98       0.3004       114.06       0.9075         Present       1.32       120.61       0         Translocation t(4;14)       1.98       0.5287       114.06       0.8828         Present       1.98       0.5287       114.06       0.8828         Present       1.98       0.5287       114.06       0.8828         Present       1.83       -       120.61       -         Absent       1.83       -       120.61       -         Absent       0.75       57.03       -       -         Absent       1.92       0.3062       119.40       0.4326         Present       2.07       105.22       -       -         Stage of chronic kidney disease       1.97       0.6186       113.63       0.5978         G1       1.54       137.58       -       -       -         G2       1.76       120.34       -       -	3	1.80		111.89	
Absent       1.98       0.3004       114.06       0.9075         Present       1.32       120.61       120.61         Translocation t(4;14)       1.98       0.5287       114.06       0.8828         Present       1.38       0.5287       114.06       0.8828         Present       1.38       125.14       0.5287       114.06       0.8828         Translocation t(4;16)       1.83       -       120.61       -         Absent       1.83       -       120.61       -         Present       0.75       57.03       -       -         Renal function       1.92       0.3062       119.40       0.4326         B       2.07       105.22       0.5287       0.5978         G1       1.54       137.58       0.5978         G2       1.76       120.34       0.5978	Deletion 17p				
Present       1.32       120.61         Translocation t(4;14)       1.98       0.5287       114.06       0.8828         Present       1.38       125.14       0.5287       114.06       0.8828         Present       1.38       125.14       0.5287       114.06       0.8828         Translocation t(4;16)       1.83       -       120.61       -         Absent       1.83       -       120.61       -         Present       0.75       57.03       -         Renal function       1.92       0.3062       119.40       0.4326         B       2.07       105.22       105.22       105.22         Stage of chronic kidney disease       1.97       0.6186       113.63       0.5978         G1       1.54       137.58       137.58       120.34	Absent	1.98	0.3004	114.06	0.9075
Translocation t(4;14)         Absent       1.98       0.5287       114.06       0.8828         Present       1.38       125.14       0.8828         Translocation t(4;16)       1.83       -       120.61       -         Absent       1.83       -       57.03       -       -         Present       0.75       57.03       -       -       -       -         Renal function       1.92       0.3062       119.40       0.4326       - <td>Present</td> <td>1.32</td> <td></td> <td>120.61</td> <td></td>	Present	1.32		120.61	
Absent       1.98       0.5287       114.06       0.8828         Present       1.38       125.14       125.14         Translocation t(4;16)       1.83       -       120.61       -         Absent       1.83       -       120.61       -         Present       0.75       57.03       -       -         Renal function       1.92       0.3062       119.40       0.4326         B       2.07       105.22       105.22         Stage of chronic kidney disease       1.97       0.6186       113.63       0.5978         G1       1.54       137.58       0.5978	Translocation t(4;14)				
Translocation t(4;16)     1.83     -     120.61     -       Absent     1.83     -     57.03     -       Present     0.75     57.03     -       Renal function     1.92     0.3062     119.40     0.4326       B     2.07     105.22     -       Stage of chronic kidney disease     1.97     0.6186     113.63     0.5978       G1     1.54     137.58     -     120.34	Absent Present	1.98 1.38	0.5287	114.06 125.14	0.8828
Absent       1.83       -       120.61       -         Present       0.75       57.03       -         Renal function       1.92       0.3062       119.40       0.4326         B       2.07       105.22       105.22         Stage of chronic kidney disease       1.97       0.6186       113.63       0.5978         G1       1.54       137.58       120.34	Translocation t(4:16)				
Adden     1.05     120.01       Present     0.75     57.03       Renal function     1.92     0.3062     119.40     0.4326       B     2.07     105.22       Stage of chronic kidney disease     1.97     0.6186     113.63     0.5978       G1     1.54     137.58       G2     1.76     120.34	Absent	1.83	_	120.61	_
Renal function       1.92       0.3062       119.40       0.4326         B       2.07       105.22         Stage of chronic kidney disease       1.97       0.6186       113.63       0.5978         G1       1.54       137.58       120.34	Present	0.75		57.03	
A1.920.3062119.400.4326B2.07105.22Stage of chronic kidney disease1.970.6186113.630.5978G11.54137.58G21.76120.34	Renal function				
B     2.07     105.22       Stage of chronic kidney disease     1.97     0.6186     113.63     0.5978       G1     1.54     137.58       G2     1.76     120.34	А	1.92	0.3062	119.40	0.4326
Stage of chronic kidney disease       1.97       0.6186       113.63       0.5978         G1       1.54       137.58         G2       1.76       120.34	В	2.07		105.22	
G2 1.76 120.34	Stage of chronic kidney disease G1	1.97 1.54	0.6186	113.63 137.58	0.5978
	G2	1.76		120.34	

#### Table 1 (continued)

Variable	NLR	р	PLR	р	
	Me		Me		
G3a	2.32		146.00		
G3b	1.84		114.06		
G4	4.74		46.58		
G5D	1.49		93.39		
G1	1.97	0.3406	118.46	0.6207	
G2, G3a, G3b, G4, G5D	1.84		114.08		
Performance status					
0	2.04	0.1244	140.44	0.5000	
1	1.48		107.25		
2	1.98		118.46		
3	2.33		127.39		
4	2.53		112.72		
0,1	1.70	0.0682	115.45	0.5125	
2–4	2.17		119.40		
Body weight loss before treatment					
No	1.80	0.0876	107.76	0.2367	
Yes	2.12		122.74		
5%	1.68	0.1344	107.49	0.2040	
10%	2.31		127.27		
Anemia grade before treatment (WHO)					
Absent	1.84	0.5366	154.38	0.5630	
I (mild)	2.12		185.23		
II (moderate)	1.76		163.14		
III (severe)	2.20		130.77		
IV (life-threatening)	1.31		162.10		
Absent	1.84	0.3920	119.21	0.9633	
I (mild), II (moderate), III (severe), IV (life-threatening)	2.06		115.45		

0.0112; HR = 5.73, 95% CI 1.50–21.95), and high NLR (*p* = 0.0048; HR = 3.83, 95% CI 1.51–9.71).

## Discussion

A number of both experimental and clinical studies confirm the existence of a close relationship between chronic inflammation and malignancy, in virtually all of its stages: initiation, promotion, and progression [6–9]. Inflammatory cells capable of releasing a number of cytokines and growth factors cause damage to DNA, promote angiogenesis and lymphangiogenesis, and stimulate complex mechanisms of "escape" of malignant cells [10].

It has been reported that an increased number of lymphocytes infiltrating a tumor may be one of the markers of good prognosis [11-13]. In turn, the increase in the number of neutrophils or lymphopenia weakens the mechanisms of destruction of malignant cells, which promotes the formation of distant metastases [14]. Elevated values of neutrophils to lymphocytes ratio (NLR)—as an indicator of active infectionare associated with worse prognosis, weaker response to treatment, and shorter survival in patients with solid tumors [15].

Similar significance is attributed to the platelet to lymphocytes ratio (PLR)) [16, 17]. According to estimates, in up to 60% of patients with malignant tumors, thrombocythemia has a significant, unfavorable impact on the prognosis. Through complex mechanisms of hemostasis activation as well as cell signal transduction, an increased number of PLT stimulates cell proliferation and promotes metastasis [18, 19].

Bone marrow microenvironment and the way it interacts with myeloma cells are crucial in the pathogenesis of MM. The stromal environment determines the processes of growth, survival, migration, proliferation, and resistance to the treatment of neoplastically changed plasmocytes. Bone marrow stromal cells (BMSC), endothelial cells, and especially adhesion molecules on their surface have been shown to be critically important for the development of the disease. Their interactions through a series of proinflammatory cytokines released by BMSC and/or myeloma cells induce signaling pathways of proliferation and survival of monoclonal plasmocytes [20]. Therefore, all cells involved in the development of the

 
 Table 2
 Spearman's correlation

 between selected demographicclinical and laboratory factors and NLR and PLR

Variable	NLR		PLR		
	rho	р	rho	р	
Age	-0.060	0.5520	-0.166	0.0995	
Durie-Salmon stage	0.171	0.0899	0.024	0.8142	
ISS stage	-0.025	0.8022	-0.114	0.2592	
Performance status	0.197	0.0492	0.006	0.9519	
Percentage of plasmocytes	-0.027	0.7941	-0.196	0.0514	
Anemia grade before treatment (WHO)	0.037	0.7133	-0.105	0.2970	
HGB	-0.061	0.5483	0.077	0.4443	
eGFR	-0.037	0.7137	0.029	0.7711	
Stage of chronic kidney disease	0.064	0.5287	-0.016	0.8781	
ALB	-0.082	0.4200	-0.056	0.5774	
CREA	0.144	0.1516	-0.078	0.4421	
ALP	-0.048	0.7009	0.017	0.8917	
B2M	-0.035	0.7327	-0.143	0.1610	
LDH	-0.020	0.8569	-0.148	0.1741	
Calcium	0.223	0.0258	0.154	0.1249	
CRP	0.449	< 0.0001	0.225	0.0311	
Time to auto-HSCT	-0.073	0.6164	0.025	0.8662	
BMI	-0.183	0.2237	-0.300	0.0429	
NLR and PLR	0.453, 0.00	091			

so-called systemic inflammatory response could be important in the course of the disease.

There are only a few reports in the literature in which the NLR and PLR ratios were assessed in the context of prognosis or treatment efficacy in patients with MM.

Kelkitli et al. were the first to evaluate the value of NLR in patients with MM. The study included 151 patients and 151 healthy volunteers, appropriately selected for age and sex. NLR was significantly higher in myeloma patients than in the control group  $(2.79 \pm 1.82 \text{ vs. } 1.9 \pm 0.61$ , respectively, p < 0.0001). It has been shown that NLR is an independent prognostic factor for OS and EFS (event-free survival) estimation. Patients with NLR < 2 at the time of diagnosis obtained longer OS compared to patients with NLR  $\geq 2$  (5-year OS were 87.5 and 42.4%, respectively, p < 0.0001). Similarly, longer EFS was observed in patients with NLR < 2 compared to patients with NLR  $\geq 2$  (5-year EFS rates were 88.4 and 41.8%, respectively, p < 0.0001) [21].

Once et al. performed a retrospective analysis of 52 patients with MM. They showed that the NLR index depends on the concentration of CRP and  $\beta$ 2-microglobin (p = 0.02, p =0.001). They observed that patients with NLR > 1.72 were in a significantly higher stage of disease and had worse performance status and renal function. Median OS for the whole group was estimated at 35.1 months, and there was a significant difference in OS depending on the NLR (42.75 months for patients with NLR  $\leq$  1.72 and 26.14 months for patients with NLR > 1.72, *p* = 0.04) [22].

Romano et al. assessed the importance of the NLR index in relation to the efficacy of myeloma treatment with the use of immunomodulatory drugs (IMiDs) and proteasome inhibitors in various regimens with or without glucocorticoids. Three hundred nine patients were recruited for the study. Authors did not show a relationship between the NLR and the efficacy of single or double drug treatment regimens. However, they observed significant differences in the prognosis of patients treated with autologous bone marrow transplantation (ASCT). The median PFS was 22.1 in patients with NLR  $\geq$  2, versus 43.4 months in the NLR < 2 group (p = 0.017). In the group of patients with NLR  $\geq$  2 OS was 57.6 months, in the remaining subjects median OS was not reached (p = 0.002). Based on those findings, the authors proposed adding NLR to the ISS classification. They divided the subjects into three groups: very low risk—ISS1 and NLR <2, very high risk—ISS3 and NLR  $\geq 2$ , and the others were qualified for the standard risk group. They observed significant differences in the 5-year PFS depending on the ISS-NLR classification, respectively 39.3, 19.4, and 10.9% for the very low, standard, and very high risk groups. Five-year OS was 95.8, 50.9, and 23.6% for very low, standard, and very high risk patients according to ISS-NLR. Interestingly, the ISS classification itself was insufficient to differentiate patients against PFS and OS [23].

**Table 3** The influence of selected factors on the risk of PFS and OS shortening in multivariate analysis (Cox logistic regression model) (model adjustment for PFS: p < 0.0001;  $\chi^2 = 41.40$  and OS: p < 0.0001;  $\chi^2 = 44.24$ )

Progressic	Progression free survival				Overall survival			
β	р	HR	95% CI	β	р	HR	95% CI	
-0.17	0.6935	0.84	0.35–1.99	2.56	0.0012	12.88	2.75-60.34	
0.80	0.1090	2.22	0.84–5.86	0.81	0.1331	2.24	0.79–6.39	
2.72	< 0.0001	15.18	4.98-46.26	1.35	0.0218	3.84	1.22-12.07	
0.10	0.8333	1.11	0.43–2.82	0.98	0.0745	2.65	0.91–7.71	
ney disease	0.0054	0.00			0.1016	1.05		
-1.28	0.0864	0.28	0.06–1.19	1.47	0.1016	4.35	0.75-25.03	
eatment	0.2020	2.24	1.0( 10.52	2.42	0.0001	11.20	2 50 27 09	
0.75	0.2039	5.54	1.06–10.53	2.43	0.0001	11.39	3.30-37.08	
1.24	0.0021	2 47	1 59 7 64	1 10	0.0225	2 28	1 19 0 11	
1.24	0.0021	5.47	1.56-7.04	1.19	0.0233	5.20	1.10-9.11	
1 75	0.0112	5 73	1 50-21 95	-0.07	0.9198	0.93	0 22-3 98	
1.75	0.0112	5.75	1.50 21.95	0.07	0.9190	0.95	0.22 5.90	
1.34	0.0048	3.83	1.51-9.71	1.61	0.0133	5.00	1.41-17.75	
-0.62	0.1787	0.54	0.22-1.32	0.94	0.0496	2.56	1.01-6.51	
	$\frac{\text{Progressic}}{\beta}$ -0.17 0.80 2.72 0.10 ey disease -1.28 eatment 0.75 1.24 1.75 1.34 -0.62	Progression free survival $\beta$ $p$ $-0.17$ $0.6935$ $0.80$ $0.1090$ $2.72$ $< 0.0001$ $0.10$ $0.8333$ ney disease $-1.28$ $-1.28$ $0.0864$ eatment $0.75$ $0.75$ $0.2039$ $1.24$ $0.0021$ $1.75$ $0.0112$ $1.34$ $0.0048$ $-0.62$ $0.1787$	Progression free survival $\beta$ $p$ HR           -0.17         0.6935         0.84           0.80         0.1090         2.22           2.72         <0.0001	Progression free survival $\beta$ $p$ HR95% CI $-0.17$ 0.69350.840.35–1.990.800.10902.220.84–5.862.72<0.0001	Progression free survival         Overall st $\beta$ $p$ HR         95% CI $\beta$ -0.17         0.6935         0.84         0.35-1.99         2.56           0.80         0.1090         2.22         0.84-5.86         0.81           2.72         <0.001	Progression free survival         Overall survival $\beta$ $p$ HR         95% CI $\beta$ $p$ -0.17         0.6935         0.84         0.35–1.99         2.56         0.0012           0.80         0.1090         2.22         0.84–5.86         0.81         0.1331           2.72         < 0.0001	Progression free survival         Overall survival $\beta$ $p$ HR         95% CI $\beta$ $p$ HR           -0.17         0.6935         0.84         0.35-1.99         2.56         0.0012         12.88           0.80         0.1090         2.22         0.84-5.86         0.81         0.1331         2.24           2.72         <0.001	



Fig. 3 a ROC curve illustrating response detection after 6-th cycle of CTH according to NLR value. b ROC curve illustrating response detection after 8-th cycle of CTH according to PLR value





Fig. 4 a Kaplan-Meier curves illustrating PFS differences between patients with low and high NLR. b Kaplan-Meier curves illustrating OS differences between patients with low and high NLR. c Kaplan-Meier

The results of two meta-analyses assessing the prognostic value of NLR in the course of the disease have also been published. Mu et al. analyzed 7 clinical trials involving a cohort of 1971 patients with myeloma and observed that elevated pre-treatment NLR was significantly associated with high stage of the disease according to the ISS (III vs. ISS I-II: OR 2427, 95% CI 1.268-4.467) as well as Durie-Salmon (III vs. I-II: OR 1.738, 95% CI 1.123-2.665) scales. Elevated NLR was associated with shorter OS (HR 2.084, 95% CI 1.341-3.238) and median PFS (HR 1.029, 95% CI 1.016-1.042). A linear relationship was found between increased NLR and mortality risk in patients with MM [24]. Zeng et al. analyzed the PubMed, Cochrane, and Embase databases. They studied data from eight clinical trials conducted jointly on a group of 1886 patients in 2013-2017. They reached the same conclusionssignificantly shorter OS (HR 1.73, 95% CI 1.23-2.44, p = 0.002) and PFS (HR 1.74, 95% CI 1.11–2.73, p = 0.015) were noted in patients with NLR elevated prior to treatment. They also suggested that NLR correlates with the ISS stage of

curves illustrating OS differences between patients with low and high PLR

disease, the isotype of the disease, and the response to treatment [25].

The evaluation of the prognostic value of NLR and PLR in MM was also the subject of research by Li et al. Three hundred fifteen patients were randomized to receive regimens with bortezomib, thalidomide, and classic cytostatics. The cut-off points for the indicators were determined based on the analysis of the ROC curve—for NLR–2, for PLR–155. The authors confirmed that high NLR observed before treatment is an independent, unfavorable prognostic factor. However, they did not demonstrate a relationship between the PLR value, PFS, and OS time [26].

In a similar publication evaluating the importance of hematological indices of inflammation, Shi et al. confirmed the relationship between high NLR and MLR (monocyte-to-lymphocyte ratio) with unfavorable prognosis. In the case of PLR, they observed an inverse correlation; low values were associated with a shorter PFS: 32.3 vs. 40.4 months (p = 0.005) and OS 49.4

Ann Hematol (2020) 99:2881–2891

vs. 53.2 months (p = 0.008). The study was conducted in a group of 559 patients; the authors did not refer to the type of treatment used. Four (NLR), 100 (PLR), and 0.3 (MLR) were set as cut-off points [27].

The relationship between decreased PLR and prognosis in myeloma patients was confirmed in another study by Solmaz et al. Researchers recruited a cohort of 186 patients treated with chemotherapy containing vincristine/doxorubicine/dexamethasone (n = 100), cyclophosphamide/dexamethasone (n = 34), bortezomib/dexamethasone (n = 21), and others. They set following cut off points: 1.9 (NLR), 120.00 (PLR), and 0.27 (MLR) [28].

In contrast to the cited publications, in our study, we found a relationship between elevated PLR and shorter OS (40 vs. 78 months; HR = 2.15, 95% CI 1.07–4.33; p = 0.0058). Interestingly, high PLRs were observed in patients with low BMI and high serum CRP. In the current studies, patients treated with thalidomide-based regimen have not been isolated, which makes interpretation of the obtained results much more difficult.

# Conclusions

The results of our study confirm that simple, routinely available parameters, namely NLR and PLR, can be reliable, useful prognostic markers in estimating the survival of patients with MM. Furthermore, NLR can be a predictive marker for thalidomide based chemotherapy.

Results regarding the importance of NLR are mostly consistent with earlier observations. Differences observed with regard to PLR may result from the selection of the group in terms of the treatment used, and indicate the need to continue research on larger groups of subjects.

Author contributions A.SzSz. was a major contributor in writing the manuscript. A.SzSz., M.M., M.Sz, A.N., K.K, Sz.Z., J.S. participated in the collection of data and data interpretation. R.M, A.F., T.MM., M.H. contributed to the data analysis and interpretation. All authors contributed to writing and review of the manuscript.

Funding This research received no external funding.

#### **Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

All patients provided written informed consent The study was approved by the Ethics Committee of Medical University of Lublin (Approval No. KE-0254/77/2019).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

#### References

- Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, Miguel JFS (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. https://doi.org/10. 1016/S1470-2045(14)70442-5
- Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 28(5): 1122–1128. https://doi.org/10.1038/leu.2013.313
- Greipp PR, San Miguel J, Durie BGM et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412– 3420. https://doi.org/10.1200/JCO.2005.04.242
- Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863–2869. https://doi.org/10.1200/JCO.2015.61.2267
- Podar K, Chauhan D, Anderson KC (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 23(1):10–24. https://doi.org/10.1038/leu.2008. 259
- Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell. 140(6):883–899. https://doi.org/10.1016/j. cell.2010.01.025
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell. 144(5):646–674. https://doi.org/10.1016/j.cell. 2011.02.013
- Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125(9):3347– 3355. https://doi.org/10.1172/JCI80007
- Wang D, DuBois RN (2015) Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 36(10):1085–1093. https://doi.org/10.1093/carcin/ bgv123
- de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24–37. https://doi.org/10.1038/nrc1782
- 11. Shau HY, Kim A (1988) Suppression of lymphokine-activated killer induction by neutrophils. J Immunol 141(12):4395–4402

- Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis. Cell. 103(3):481–490. https://doi.org/10.1016/ S0092-8674(00)00139-2
- Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey J-N (2009) Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614–622. https://doi.org/10. 1245/s10434-008-0267-6
- el Aziz LMA (2014) Blood neutrophil–lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4. Med Oncol 31(12):311. https://doi. org/10.1007/s12032-014-0311-2
- Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, Timmerman R (2015) Neutrophil-lymphocyte and plateletlymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol 10(2):280–285. https://doi.org/10.1097/JTO.000000000000399
- Templeton AJ, Ace O, McNamara MG et al (2014) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 23(7):1204– 1212. https://doi.org/10.1158/1055-9965.EPI-14-0146
- Zhou X, Du Y, Huang Z et al (2014) Prognostic value of PLR in various cancers: a meta-analysis. PLoS One 9(6):e101119. https:// doi.org/10.1371/journal.pone.0101119
- Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T (2002) Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 9(3):287–291. https://doi.org/10.1007/BF02573067
- Nie D, Yang E, Li Z (2019) Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis. BMC Cancer 19(1):73. https://doi.org/ 10.1186/s12885-018-5264-y
- Reagan MR, Ghobrial IM (2012) Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin cancer Res an Off J Am Assoc Cancer Res 18(2):342–349. https://doi.org/10.1158/1078-0432.CCR-11-2212
- 21. Kelkitli E, Atay H, Cilingir F et al (2014) Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte

2891

ratio. Ann Hematol 93(5):841-846. https://doi.org/10.1007/ s00277-013-1978-8

- Onec B, Okutan H, Albayrak M et al (2017) The predictive role of the neutrophil/lymphocyte ratio in survival with multiple myeloma: a single center experience. J Clin Lab Anal 31(2). https://doi.org/10. 1002/jcla.22032
- Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, di Raimondo F, Borrello I (2015) Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann Hematol 94(11):1875–1883. https://doi.org/10.1007/s00277-015-2462-4
- Mu S, Ai L, Fan F, Sun C, Hu Y (2018) Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a doseresponse meta-analysis. Onco Targets Ther 11:499–507. https:// doi.org/10.2147/OTT.S153146
- Zeng Q, Liu Z, Li Q, Liu T (2018) Prognostic value of neutrophil to lymphocyte ratio and clinicopathological characteristics for multiple myeloma: a meta-analysis. Medicine (Baltimore) 97(41): e12678. https://doi.org/10.1097/MD.00000000012678
- Li Y, Li H, Li W et al (2017) Pretreatment neutrophil/lymphocyte ratio but not platelet/lymphocyte ratio has a prognostic impact in multiple myeloma. J Clin Lab Anal 31(5). https://doi.org/10.1002/ jcla.22107
- Shi L, Qin X, Wang H et al (2017) Elevated neutrophil-tolymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget 8(12):18792–18801. https://doi.org/ 10.18632/oncotarget.13320
- Solmaz S, Uzun O, Acar C, Sevindik OG, Piskin O, Ozsan HG, Demirkan F, Undar B, Alacacioglu A, Ozcan MA, Alacacioglu I (2018) Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma? J Lab Physicians 10(4):363–369. https://doi. org/10.4103/JLP.JLP\_36\_18

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.